Bimatoprost: Mechanism of ocular surface hyperemia associated with topical therapy

Cardiovascular Drug Reviews

Volumn 23, Issue 3, 2005, Pages 231-246

  Chen, June ^a   Dinh, Tim ^a   Woodward, David F ^a   Holland, J Michael ^a   Yuan, Yang Dar ^a   Lin, Tsung Hua ^a   Wheeler, Larry A ^a  

^a ALLERGAN INC   (United States)

Author keywords

Bimatoprost; Conjunctiva; Hyperemia; Inflammation; Latanoprost; Nitric oxide; Prostaglandin E2

Indexed keywords

ANTIGLAUCOMA AGENT; BIMATOPROST; INDOMETACIN; LATANOPROST; N(G) NITROARGININE METHYL ESTER; PROSTAGLANDIN E2;

CONJUNCTIVAL HYPEREMIA; DOG; DRUG APPROVAL; DRUG SAFETY; DRUG TOLERABILITY; EYE TOXICITY; GLAUCOMA; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; INFLAMMATION; INTRAOCULAR PRESSURE; JUGULAR VEIN; NONHUMAN; PRIMATE; PRIORITY JOURNAL; RABBIT; REVIEW; UNITED STATES; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 27644476038     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2005.tb00168.x     Document Type: Review

References (45)

1. Abelson MB, Mroz M, Rosner SA, Dirks MS, Hirabayashi D. Multicenter, open-label evaluation of hyperemia associated with use of bimatoprost in adults with open-angle glaucoma or ocular hypertension. Adv Ther 2003;20:1-13.
2. Albrecht EW, Stegeman CA, Heeringa P, Henning RH, van Goor H. Protective role of endothelial nitric oxide synthase. J Pathol 2003;199:8-17.
3. Aboulafia J, Mendes GB, Miyamoto ME, Paiva ACM, Paiva TB. Effect of indomethacin and prostaglandin on the smooth muscle contracting activity of angiotensin and other agonists. Br J Pharmacol 1976;58:223-228.
4. Alster P, Wennmalm Å. Effect of nicotine on prostacyclin formation in rat aorta. Eur J Pharmacol 1983;86:441-446.
5. 2α-induced ocular hyperemia. Exp Eye Res 1994;59:401-408.
6. 2α- and latanoprost acid-induced relaxation of submental veins. Eur J Pharmacol 1997;340:195-201.
7. 2α-induced ocular surface hyperemia by sensory nerves in rabbits. Curr Eye Res 1997;16:886-890.
8. 2α, and latanoprost acid on isolated ocular blood vessels in vitro. J Ocul Pharmacol 1998;14:119-128.
9. 2 and acetylcholine from guinea-pig isolated ileum at rest and during field stimulation. Br J Pharmacol 1974;50:119-124.
10. Chen J, Champa-Rodriguez ML, Woodward DF. Identification of a prostanoid FP receptor population producing endothelium-dependent vasorelaxation in the rabbit jugular vein. Br J Pharmacol 1995;116:3035-3041.
11. Chen J, Woodward DF, Coleman RA, Jones RL, Lydford SJ. Prostanoid receptor assays Unit 4.18. In: Enna SJ, Williams M, Ferkany JW, Kenakin T, Porsolt RD, Sullivan JP, eds. Current protocols in pharmacology. New York: John Wiley & Sons, Inc., 2001;4.18.1-4.18.41.
12. 2α and related compounds. Adv Exp Med Biol 2002;507:331-336.
13. Chen J, Woodward DF. Lumigan®: A novel drug for glaucoma therapy. Optometry Pract 2002;3:95-102.
14. Chen J, Susanna R Jr, David R, Woodward DF, Holland JM, Wheeler LA. Conjunctival hyperemia related to bimatoprost treatment is not associated with signs of inflammation. Invest Ophthalmol Vis Sci 2004;45:ARVO E-Abstract 2609.
15. Chen J, Senior J, Marshall K, et al. Studies using isolated uterine and other preparations show bimatoprost and prostanoid FP agonists have different activity profiles. Br J Pharmacol 2005;144:493-501.
16. Cirino G, Fiorucci S, Sessa WC. Endothelial nitric oxide synthase: The Cinderella of inflammation? Trends Pharmacol Sci 2003;24:91-95.
17. Cohen JS, Gross RL, Cheetham JK, VanDenburgh AM, Bernstein P, Whitcup SM. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol 2004;49:S45-S52.
18. Christiansen GA, Nau CB, McLaren JW, Johnson DH. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology 2004;111:1658-1662.
19. DuBiner H, Cooke D, Dirks M, Stewart WC, VanDenburgh AM, Felix C. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: A 30-day comparison with latanoprost. Surv Ophthalmol 2001;45(Suppl 4):S353-S360.
20. Eisenberg DL, Toris CB, Camras CB. Bimatoprost and travoprost: A review of recent studies of two new glaucoma drugs. Surv Ophthalmol 2002;47:S105-S115.
21. Ferreira SH, Herman AG, Vane JR. Prostaglandin production by rabbit isolated jejunum and its relationship to the inherent tone of the preparation. Br J Pharmacol 1976;56:469-477.
22. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-376.
23. Gandolfi SA, Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology 2003;110:609-614.
24. Goodfriend TL, Simpson RU. Angiotensin receptors in bovine umbilical artery and their inhibition by non-steroidal anti-inflammatory drugs. Br J Pharmacol 1981;72:247-255.
25. Guenoun J-M, Baudouin C, Rat P, Pauly A, Wamet J-M, Brignole-Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci 2005;46:2444-2450.
26. Haye-Legrand I, Cerrina J, Raffestin B, et al. Histamine contraction of isolated human airway muscle preparations: Role of prostaglandins. J Pharmacol Exp Ther 1986;239:536-541.
27. Higginbotham EJ, Schuman JS, Goldberg I, et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 2002;120:1286-1293.
28. Kim JC, Park GS, Kim JK, Kim YM. The role of nitric oxide in ocular surface cells. J Korean Med Sci 2002;17:389-394.
29. Koss MC. Functional role of nitric oxide in regulation of ocular blood flow. Eur J Pharmacol 1999;374:161-174.
30. Leal BC, Medeiros FA, Medeiros FW, Santo RM, Susanna Jr R. Conjunctival hyperemia associated with bimatoprost use: A histopathologic study. Am J Ophthalmol 2004;138:310-313.
31. Lumigan (Bimatoprost) Ophthalmic Solution. Pharmacology Review of New Drug Application 21-275. FDA/Center for Drug Evaluation and Research. 2001;Part 1 and Part 2:1-107. Available online at http://www.fda.gov/cder/foi/nda/2001/ 21275_Lumigan.htm.
32. Mroz M, Abelson MB. Ocular surface changes associated with the use of bimatoprost 0.03%. Invest Ophthalmol Vis Sci 2003;44:ARVO E-Abstract 4417.
33. Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003;135:55-63.
34. Northover BJ. Mechanism of the inhibitory action of indomethacin on smooth muscle. Br J Pharmacol 1971;41:540-551.
35. Parrish RK, Palmberg P, Sheu W-P. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135:688-703.
36. Rees DD, Palmer RMJ, Schulz R, Hodson HF, Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 1990;101:746-752.
37. 2+ channel current in myometrial smooth muscle from pregnant women. Br J Pharmacol 1998;125:1212-1217.
38. Schmetterer L, Polak K. Role of nitric oxide in the control of ocular blood flow. Prog Retin Eye Res 2001;20:823-847.
39. 2α selectively stimulate intracellular calcium signaling in different cat iris sphincter cells. Exp Eye Res 2005;80:135-145.
40. Stewart WC, Kolker AE, Stewart JA, Leech J, Jackson AL. Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. Am J Ophthalmol 2003;135:314-320.
41. Stjernschantz J, Selén G, Astin M, Resul B. Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment. Prog Retin Eye Res 2000;19:459-496.
42. Williams RD. Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost. Adv Ther 2002;19:275-281.
43. Woodward DF, Krauss AH-P, Chen J, et al. The pharmacology of bimatoprost (Lumigan™). Surv Ophthalmol 2001;45:S337-S345.
44. Woodward DF, Krauss AH-P, Chen J, et al. Pharmacological characterization of a novel antiglaucoma agent, bimatoprost (AGN 192024). J Pharmacol Exp Ther 2003;305:772-785.
45. Woodward DF, Phelps RL, Krauss AH-P, et al. Bimatoprost: A novel antiglaucoma agent. Cardiovasc Drug Rev 2004;22:103-120.